XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Stockholders' Equity (Tables)
9 Months Ended
Mar. 31, 2023
Stockholders' Equity  
Schedule of stock-based compensation expense in the consolidated statements of operations

We recorded stock-based compensation expense in the consolidated statements of operations as follows (in thousands):

Three Months Ended March 31, 

    

Nine Months Ended March 31, 

    

2022

    

2023

2022

    

2023

Cost of goods sold

$

205

$

229

$

616

$

686

Selling, general and administrative

6,567

6,757

 

19,977

 

20,467

Research and development

126

126

 

393

 

375

Stock-based compensation expense

$

6,898

$

7,112

$

20,986

$

21,528

Schedule of stock option activity

Weighted

Average

Weighted-Average

Aggregate

Number of

Exercise

Remaining Contractual

Intrinsic Value

    

Options

    

Price

    

Term

    

(in thousands)

Outstanding at June 30, 2022

 

110,645

 

82.43

 

Granted

 

23,351

87.90

Exercised

 

(19,614)

67.83

Expired or forfeited

 

(1,568)

81.60

Outstanding at March 31, 2023

 

112,814

86.11

6.8 years

$

1,833

Exercisable at March 31, 2023

67,689

 

5.4 years

$

1,274

Schedule of stock option activity

Weighted-

Average

    

Shares

    

Fair Value

Nonvested at June 30, 2022

 

427,447

$

90.17

Granted

 

356,694

89.11

Vested

 

(312,038)

96.42

Forfeited

 

(13,814)

88.82

Nonvested at March 31, 2023

 

458,289

$

85.13